Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 49

1.

The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19.

Braendstrup P, Levine BL, Ruella M.

Cytotherapy. 2020 Jan 31. pii: S1465-3249(19)30918-1. doi: 10.1016/j.jcyt.2019.12.004. [Epub ahead of print] Review.

PMID:
32014447
2.

Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T cell dysfunction.

Singh N, Lee YG, Shestova O, Ravikumar P, Hayer KE, Hong SJ, Lu XM, Pajarillo R, Agarwal S, Kuramitsu S, Orlando EJ, Mueller KT, Good CR, Berger SL, Shalem O, Weitzman MD, Frey NV, Maude SL, Grupp SA, June CH, Gill S, Ruella M.

Cancer Discov. 2020 Jan 30. pii: CD-19-0813. doi: 10.1158/2159-8290.CD-19-0813. [Epub ahead of print]

PMID:
32001516
3.

Beat pediatric ALL MRD: CD28 CAR T and transplant.

Ruella M, Locke FL.

Blood. 2019 Dec 26;134(26):2333-2335. doi: 10.1182/blood.2019003821. No abstract available.

PMID:
31877213
4.

A cellular antidote to specifically deplete anti-CD19 chimeric antigen receptor positive cells.

Ruella M, Barrett DM, Shestova O, Perazzelli J, Posey AD, Hong SJ, Kozlowski M, Lacey SF, Melenhorst JJ, June CH, Gill S.

Blood. 2019 Nov 8. pii: blood.2019001859. doi: 10.1182/blood.2019001859. [Epub ahead of print]

PMID:
31703119
5.

Dynamic Changes in Gene Mutational Landscape With Preservation of Core Mutations in Mantle Cell Lymphoma Cells.

Zhang Q, Wang HY, Liu X, Roth MH, Shestov AA, Lee SC, Jain K, Soderquist C, Xiong QB, Ruella M, Strauser H, Glickson JD, Schuster SJ, Ptasznik A, Wasik MA.

Front Oncol. 2019 Jul 3;9:568. doi: 10.3389/fonc.2019.00568. eCollection 2019.

6.

Influence of Donor and Recipient Gender on Telomere Maintenance after Umbilical Cord Blood Cell Transplantation: A Study by the Gruppo Italiano Trapianto Di Midollo Osseo.

Derenzini E, Risso A, Ruella M, Spatola T, Milone G, Pioltelli P, Iori AP, Santarone S, Bosi A, Rambaldi A, Bacigalupo AP, Arcese W, Tarella C.

Biol Blood Marrow Transplant. 2019 Jul;25(7):1387-1394. doi: 10.1016/j.bbmt.2019.03.026. Epub 2019 Mar 30.

PMID:
30935966
7.

Emerging Cellular Therapies for Cancer.

Guedan S, Ruella M, June CH.

Annu Rev Immunol. 2019 Apr 26;37:145-171. doi: 10.1146/annurev-immunol-042718-041407. Epub 2018 Dec 10.

PMID:
30526160
8.

Novel Immunotherapies for T Cell Lymphoma and Leukemia.

Ghione P, Moskowitz AJ, De Paola NEK, Horwitz SM, Ruella M.

Curr Hematol Malig Rep. 2018 Dec;13(6):494-506. doi: 10.1007/s11899-018-0480-8. Review.

9.

Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell.

Ruella M, Xu J, Barrett DM, Fraietta JA, Reich TJ, Ambrose DE, Klichinsky M, Shestova O, Patel PR, Kulikovskaya I, Nazimuddin F, Bhoj VG, Orlando EJ, Fry TJ, Bitter H, Maude SL, Levine BL, Nobles CL, Bushman FD, Young RM, Scholler J, Gill SI, June CH, Grupp SA, Lacey SF, Melenhorst JJ.

Nat Med. 2018 Oct;24(10):1499-1503. doi: 10.1038/s41591-018-0201-9. Epub 2018 Oct 1.

10.

Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy).

Ascierto PA, Brugarolas J, Buonaguro L, Butterfield LH, Carbone D, Daniele B, Ferris R, Fox BA, Galon J, Gridelli C, Kaufman HL, Klebanoff CA, Melero I, Nathan P, Paulos CM, Ruella M, Sullivan R, Zarour H, Puzanov I.

J Immunother Cancer. 2018 Jul 11;6(1):69. doi: 10.1186/s40425-018-0377-z. Review.

11.

Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma.

Bu DX, Singh R, Choi EE, Ruella M, Nunez-Cruz S, Mansfield KG, Bennett P, Barton N, Wu Q, Zhang J, Wang Y, Wei L, Cogan S, Ezell T, Joshi S, Latimer KJ, Granda B, Tschantz WR, Young RM, Huet HA, Richardson CJ, Milone MC.

Oncotarget. 2018 May 25;9(40):25764-25780. doi: 10.18632/oncotarget.25359. eCollection 2018 May 25.

12.

Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia.

Kim MY, Yu KR, Kenderian SS, Ruella M, Chen S, Shin TH, Aljanahi AA, Schreeder D, Klichinsky M, Shestova O, Kozlowski MS, Cummins KD, Shan X, Shestov M, Bagg A, Morrissette JJD, Sekhri P, Lazzarotto CR, Calvo KR, Kuhns DB, Donahue RE, Behbehani GK, Tsai SQ, Dunbar CE, Gill S.

Cell. 2018 May 31;173(6):1439-1453.e19. doi: 10.1016/j.cell.2018.05.013. Epub 2018 May 31.

13.

Predicting Dangerous Rides in CAR T Cells: Bridging the Gap between Mice and Humans.

Ruella M, June CH.

Mol Ther. 2018 Jun 6;26(6):1401-1403. doi: 10.1016/j.ymthe.2018.05.005. Epub 2018 May 19. No abstract available.

14.

Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses.

Watanabe K, Luo Y, Da T, Guedan S, Ruella M, Scholler J, Keith B, Young RM, Engels B, Sorsa S, Siurala M, Havunen R, Tähtinen S, Hemminki A, June CH.

JCI Insight. 2018 Apr 5;3(7). pii: 99573. doi: 10.1172/jci.insight.99573. eCollection 2018 Apr 5.

15.

Building upon the success of CART19: chimeric antigen receptor T cells for hematologic malignancies.

Rotolo A, Karadimitris A, Ruella M.

Leuk Lymphoma. 2018 Sep;59(9):2040-2055. doi: 10.1080/10428194.2017.1403024. Epub 2017 Nov 22. Review.

16.

Next-Generation Chimeric Antigen Receptor T-Cell Therapy: Going off the Shelf.

Ruella M, Kenderian SS.

BioDrugs. 2017 Dec;31(6):473-481. doi: 10.1007/s40259-017-0247-0. Review.

17.

Genome-Editing Technologies in Adoptive T Cell Immunotherapy for Cancer.

Singh N, Shi J, June CH, Ruella M.

Curr Hematol Malig Rep. 2017 Dec;12(6):522-529. doi: 10.1007/s11899-017-0417-7. Review.

18.

Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells.

Ruella M, Klichinsky M, Kenderian SS, Shestova O, Ziober A, Kraft DO, Feldman M, Wasik MA, June CH, Gill S.

Cancer Discov. 2017 Oct;7(10):1154-1167. doi: 10.1158/2159-8290.CD-16-0850. Epub 2017 Jun 2.

19.

Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia.

Tasian SK, Kenderian SS, Shen F, Ruella M, Shestova O, Kozlowski M, Li Y, Schrank-Hacker A, Morrissette JJD, Carroll M, June CH, Grupp SA, Gill S.

Blood. 2017 Apr 27;129(17):2395-2407. doi: 10.1182/blood-2016-08-736041. Epub 2017 Feb 28.

20.

Walking a tightrope: clinical use of ibrutinib in mantle cell lymphoma in the elderly.

Ruella M, Soubeyran P.

Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):432-436. Review.

Supplemental Content

Loading ...
Support Center